Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 31, 2010

View Archived Issues

DermaPrep-delivered LC-002 shows promise in phase I/II trials in HIV

Preclinical and clinical data presented on BEZ-235

Efficacy and safety data from ECHO and THRIVE trials of rilpivirine reported

CADA blocks HIV entry by disrupting translocation of CD4 across ER membrane

HER2-Affitoxin is a potential therapeutic for HER2-overexpressing tumors

Repros Therapeutics submits analyzed data on Androxal to FDA

C3 Bio claims new inhibitors of proliferation of vascular smooth muscle cells

Merz Pharma patents novel NMDA receptor antagonists

Boehringer Ingelheim Pharma describes new 11-beta-HSD1 inhibitors

New antagonists of protease-activated PAR1 receptor presented

BioCancell Therapeutics completes preclinical studies of BC-821 for glioblastoma

Actavis launches risedronate in four European countries

Pfizer to purchase Akorn-Strides joint venture product portfolio

Transgenomic closes acquisition of Clinical Data's diagnostic business

Swedish Orphan Biovitrum returns rights to rozrolimupab to Symphogen

FDA approves Fortesta for hypogonadism

Meta-analysis data reported on pridopidine in Huntington's disease

Medimmune begins phase Ib/II trial of MEDI-575 in NSCLC

Compugen enters into funding agreement with Baize Investments

Immatics Biotech begins phase III IMA-901 trial in renal cell carcinoma

Axis-Shield provides update on Afinion albumin/creatinine ratio test

FG-3019 moves into phase II testing for idiopathic pulmonary fibrosis

Recordati and Merck Serono to comarket pitavastatin calcium in France

Concert Pharmaceuticals presents new deuterated NS3/NS4A protease inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...